Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dicerna Pharma (NASDAQ:DRNA), Emergent Biosolutions (NYSE:EBS) and Kala Pharmaceuticals Inc (NASDAQ:KALA).
Dicerna Pharma (DRNA)
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Dicerna Pharma. The company’s shares opened today at $14.61, close to its 52-week high of $15.80.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 34.0% and a 55.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
Currently, the analyst consensus on Dicerna Pharma is a Moderate Buy with an average price target of $15.67, implying a 7.3% upside from current levels. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock with a $20 price target.
.
See today’s analyst top recommended stocks >>
Emergent Biosolutions (EBS)
Cowen & Co. analyst Boris Peaker maintained a Hold rating on Emergent Biosolutions today and set a price target of $49. The company’s shares opened today at $56, close to its 52-week high of $60.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 13.6% and a 47.2% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Emergent Biosolutions with a $62 average price target.
Kala Pharmaceuticals Inc (KALA)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Kala Pharmaceuticals Inc, with a price target of $47. The company’s shares opened today at $12.37, close to its 52-week low of $11.81.
According to TipRanks.com, Moussatos is a 3-star analyst with an average return of 1.5% and a 42.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.
Currently, the analyst consensus on Kala Pharmaceuticals Inc is a Strong Buy with an average price target of $33.67, which is a 172.2% upside from current levels. In a report issued on August 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $35 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KALA:
